Introduction recurrent squamous cell carcinoma of the head and neck is a major cause of morbidity and portends poor survival outcomes. Despite significant advances in the treatment of head and neck squamous cell carcinoma (hnscc), the survival rate has not changed in the last decades. Magea3 is well tried for cancer immunotherapy.
Is This the SHOCKING Truth You Need to Know?
A comprehensive expression analysis of cancer testis antigens in head and neck squamous cell carcinoma revels magea3/6 as a marker for recurrence. The information below provides an overview of updates to the society for immunotherapy of cancer (sitc) clinical practice guideline on immunotherapy for the. Head and neck squamous cell carcinoma.
The current review highlights the studies on magea3 which is a ct antigen and reported in almost all types of cancer.
Head and neck cancers are the 6th most common malignancy worldwide accounting for about 600,000 new cases per year [[1], [2]]. Despite significant advances in the treatment of head and neck squamous cell carcinoma (hnscc), the survival rate has not changed in the last decades. Immunotherapy has particularly revolutionized the therapeutic landscape for head and neck squamous cell carcinoma, offering new avenues for treatment. 2 department of head and neck surgical oncology, umc utrecht cancer center, university medical center utrecht, utrecht, netherlands head and neck squamous cell.
A comprehensive expression analysis of cancer testis antigens in head and neck squamous cell carcinoma revels magea3/6 as a marker for recurrence by
